Abstract
A substantial proportion of individuals identified through hepatitis B screening are double-negative (HBsAg-negative and anti-HBs-negative) and remain fully susceptible to hepatitis B virus (HBV) infection despite the availability of an effective vaccine. PubMed, Web of Science, and CNKI were searched for literature published between January 2000 and December 2025 on barriers to HBV vaccination in double-negative populations and the interventions addressing them. Barriers operate at individual (knowledge deficits, vaccine hesitancy), service delivery (geographic inaccessibility, financial burden, disconnected screening-to-vaccination pathways), and policy (weak provider incentives, insufficient cross-sector coordination) levels. Reported interventions comprise patient-oriented strategies (reminder and recall, Health Belief Model- and Theory of Planned Behavior-based education, community engagement), provider-oriented approaches (clinical decision support, vaccination incentives, Plan-Do-Study-Act cycles), and policy-level measures (controlled temperature chain, pay-it-forward, service decentralization). Multicomponent bundles may be complementary and produce greater effects than single components; however, direct head-to-head evidence in the double-negative population is limited. Double-negative status is a convergent end-point phenotype of three immunological trajectories (never-vaccinated, vaccine non-responders, and waned immunity), and interventions should therefore be stratified accordingly. A “Screening-Education-Vaccination-Follow-up” framework is proposed, and pragmatic cluster-randomized trials with nested cost-effectiveness analyses should be prioritized.